Search tips
Search criteria 


Logo of apsbGuide for AuthorsAbout this journalExplore this journalActa Pharmaceutica Sinica. B
Acta Pharm Sin B. 2017 July; 7(4): 401–408.
Published online 2017 July 3. doi:  10.1016/j.apsb.2017.06.003
PMCID: PMC5518662

Biased activity of soluble guanylyl cyclase: the Janus face of thymoquinone


The natural compound thymoquinone, extracted from Nigella sativa (black cumin), is widely used in humans for its anti-oxidative properties. Thymoquinone is known for its acute endothelium-independent vasodilator effects in isolated rat aortae and pulmonary arteries, depending in part on activation of adenosine triphosphate-sensitive potassium channels and inhibition of voltage-dependent calcium channels. The compound also improves endothelial dysfunction in mesenteric arteries of ageing rodents and in aortae of rabbits treated with pyrogallol, by inhibiting oxidative stress. Serendipitously, thymoquinone was found to augment contractions in isolated arteries with endothelium of both rats and pigs. The endothelium-dependent augmentation it causes counterintuitively depends on biased activation of soluble guanylyl cyclase (sGC) producing inosine 3ʹ,5ʹ-cyclic monophosphate (cyclic IMP) rather than guanosine 3ʹ,5ʹ-cyclic monophosphate. This phenomenon shows a striking mechanistic similarity to the hypoxic augmentation previously observed in porcine coronary arteries. The cyclic IMP preferentially produced under thymoquinone exposure causes an increased contractility of arterial smooth muscle by interfering with calcium homeostasis. This brief review summarizes the vascular pharmacology of thymoquinone, focussing in particular on how the compound causes endothelium-dependent contractions by biasing the activity of sGC.

KEY WORDS: Thymoquinone, Endothelium-dependentcontraction, Nitric oxide, Soluble guanylyl cyclase, Cyclic IMP, NADPH:quinone oxidoreductase

Graphical abstract

This review focuses on the vascular pharmacology of the natural compound thymoquinone. Thymoquinone causes both endothelium-independent dilatations of rat arteries, and endothelium-dependent augmentations of contraction in rat and pig arteries. These augmentations counterintuitively depend on biased activity of sGC, producing cyclic IMP rather than cyclic GMP.


1. Introduction

Quinones are a class of organic substances derived from aromatic structures and include both endogenous (ubiquinone) and xenobiotic (for example, thymoquinone and 1,4-benzoquinone) compounds. Ubiquinone (coenzyme Q10) is the ubiquitous component of the mitochondrial electron transport chain, which, upon activation, generates energy from adenosine triphosphate (ATP)1.

Of xenobiotic quinones, thymoquinone (2-methyl-5-isopropyl-1,4-benzoquinone; Fig. 1) is one of the most thoroughly studied for its pharmacological properties. It is the most active component of Nigella sativa, commonly called black cumin2, 3, the essential oil of the seeds of which are used for treatment or prevention of a range of diseases and conditions including hypertension, diabetes, inflammation, infection, asthma, diarrhoea and dyslipidaemia3, 4, 5, 6. Thymoquinone has well-documented anti-oxidant, anti-inflammatory, nephro-, hepato-, neuro-protective and anticancer properties5, 6, 7, 8, 9, 10. It is, in general, safe to use with limited adverse effects; in mice, the oral median lethal dose (LD50) is estimated to be 105 mg/kg, while in patients with cancer, a dose of 2600 mg/day is well-tolerated6, 10

Fig. 1
Chemical structure of thymoquinone.

This brief review discusses the vascular properties of thymoquinone, whether administered acutely or chronically, as determined by experiments on isolated blood vessels.

2. Vasodilator effects

The in vitro vasodilator effect of thymoquinone upon acute exposure has been demonstrated in contracted isolated rat pulmonary arteries (Fig. 2A)11, rat aortae (Fig. 2B)9, 12, rat mesenteric arteries12 and porcine coronary arteries12.

Fig. 2
Relaxing effects of thymoquinone (TQ) in (A) rat pulmonary arteries during contractions to phenylephrine (PE), in the absence and presence of glibenclamide (From Suddek11, by permission), and in (B) rat aortae during contractions to either phenylephrine ...

The relaxations caused by thymoquinone are observed in the absence of endothelium. In the rat pulmonary artery they are due both to activation of ATP-sensitive potassium channels and to competitive blockade of the adrenergic, serotonin- and endothelin-pathways (Fig. 3A)11, while in the aorta of the same species they are caused partially by blockade of voltage-dependent calcium influx (Fig. 3B)9.

Fig. 3
Acute dilator effects of thymoquinone in (A) pulmonary arteries and (B) aortae of the rat. α1, α-adrenoreceptor subtype 1; 5HT, serotonin receptor; ET, endothelin receptor; IP3, inositol triphosphate; KATP, ATP-sensitive potassium (K+ ...

Upon chronic treatment with the compound, endothelial function improved in mesenteric arteries of ageing rats. This effect can, at least partially, be explained by an inhibition of oxidative stress and stabilization of the angiotensin system, leading to normalization of endothelium-dependent relaxations caused by both nitric oxide (NO) production or attributable to endothelium-dependent hyperpolarization (Fig. 4)13.

Fig. 4
Chronic effects of thymoquinone (TQ; 10 mg/kg/day by oral administration) on endothelium-dependent relaxations to acetylcholine in rat mesenteric arteries contracted to phenylephrine (PE) (From Idris-Khodja and Schini-Kerth13, by permission). ...

The facilitation of NO-dependent relaxations by chronic exposure to thymoquinone is explained, in the rat mesenteric artery, by chronic in vivo up-regulation of endothelial NO synthase (eNOS), at least to judge from the comparison of individual fluorescence intensities of the enzyme (Fig. 5)13.

Fig. 5
Chronic effects of thymoquinone (TQ; 10 mg/kg/day by oral administration) on endothelial nitric oxide synthase (eNOS) levels in rat mesenteric arteries, estimated from differences in individual fluorescence intensity (From Idris-Khodja and Schini-Kerth ...

In addition, acute exposure to the compound leads to in vitro increased NO levels and eNOS activity in the rabbit aorta (exposed to pyrogallol to cause acute endothelial dysfunction)8, in the rat aorta (Fig. 6A)14 and in cultured human umbilical vein endothelial cells (Fig. 6B)14.

Fig. 6
Western blotting of phosphorylated (at serine 1177, p-) eNOS and total (t-) eNOS in (A) rat aortae and (B) human umbilical vein endothelial cells exposed to 10–5 mol/L thymoquinone (TQ). A23, A23187 (calcium ionophore); ACh, acetylcholine ...

The above discussed vasodilator and NO-promoting effects of thymoquinone suggest that the compound may reduce the risk for atherosclerosis, caused by endothelial dysfunction among other risk factors15. In line with this suggestion, chronic treatment with thymoquinone of cholesterol-fed rabbits reduces the area of atherosclerotic lesions in their aortae16.

3. Vasoconstrictor effects

In contrast to the relaxations observed in isolated rat arteries without endothelium, in contracted rings with endothelium of rat aortae, rat mesenteric arteries (Fig. 7A) and porcine coronary arteries (Fig. 7B), thymoquinone causes a sustained augmentation12.

Fig. 7
Original tracing of isometric tension recording in precontracted (A, with 10–6 mol/L phenylephrine) rat mesenteric arteries and (B, with 10–6 mol/L serotonin) porcine coronary arteries with endothelium exposed to thymoquinone ...

The augmentation by thymoquinone in preparations with endothelium is concentration-dependent (Fig. 8A) and requires previous activation of the contractile apparatus, as it is not present in quiescent preparations12.

Fig. 8
Experimental data of the study focusing on the mechanisms underlying thymoquinone-induced augmentations in isolated rat aortae during contractions to phenylephrine. Responses to increasing concentrations of thymoquinone in preparations (A, B) with and ...

Endothelium-dependent contractions can be caused by increased production of vasoconstrictor prostanoids, endothelin-1 or augmented release of oxygen-derived free radicals17, 18, 19. However, none of these mechanisms appear to account for the augmentation to thymoquinone12. Counterintuitively, the vasoconstrictor responses to the quinone requires the presence of NO, since it is absent when endothelial NO production is inhibited (by endothelial removal or by inhibition of eNOS) and can be reinstalled by an exogenous NO donor in preparations without endothelium (Fig. 8B–C)12.

The observation that thymoquinone augments the phosphorylation of eNOS at serine 1177, and hence increases the activity of the enzyme15, 20 in both isolated arteries and cultured endothelial cells of human umbilical veins (Fig. 6)14, indicates that thymoquinone can stimulate the release of endothelium-derived NO needed for the vasoconstriction to occur.

Under most circumstances, NO is a potent endogenous vasodilator15. Therefore, its involvement in an endothelium-dependent contraction seems paradoxical, to say the least. Soluble guanylyl cyclase (sGC) is the major downstream target of NO; its inhibition results in the lack of vasoconstrictor response to thymoquinone (Fig. 8B) and hence this enzyme must play a central role in the phenomenon12. The canonical end-product of the enzymatic activity of sGC is guanosine 3′,5′-cyclic monophosphate (cyclic GMP). Production of the latter cannot explain the augmentations observed with thymoquinone, as its cell-permeable analogue, 8-bromo-cyclic GMP cannot restore the augmentations in preparations of either pig or rat arteries treated with a sGC-inhibitor12. Soluble GC can synthetize cyclic nucleotides other than cyclic GMP, in particular inosine 3ʹ,5ʹ-cyclic monophosphate (cyclic IMP), using inosine triphosphate (ITP) as a substrate 21, 22. With the use of ultra-high performance liquid chromatography (UPLC) coupled with tandem mass spectrometry (MS/MS), thymoquinone was found to increase the production of cyclic IMP (Fig. 9), but not that of cyclic GMP. The increase in intracellular cyclic IMP levels caused by the compound depends on prior eNOS- and sGC-activation (Figure 9, Figure 10)12.

Fig. 9
Measurements of cyclic IMP in isolated rat aortae precontracted with phenylephrine (10–6 mol/L) in presence or absence of thymoquinone (3×10–5 mol/L), (A) depicted in the original UPLC–MS/MS tracings and (B) quantified ...
Fig. 10
Mechanism underlying the augmentation of contraction caused by thymoquinone: role of NO/sGC pathway. Dependency of the contraction on (a) eNOS-derived NO, (b) biased activation of sGC with (c) subsequent production of cyclic IMP. cGMP, guanosine 3ʹ,5ʹ-cyclic ...

Several mechanisms appear to be involved in the cyclic IMP-mediated thymoquinone-induced augmentation; they differ depending on the blood vessel/species studied12. In porcine coronary arterial smooth muscle, thymoquinone causes the activation of Rho-associated protein kinase (ROCK; an enzyme playing a key role in the phenomenon of calcium sensitization through inhibition of myosin light chain phosphatase)23, therefore increasing the action of calcium ions on the contractile proteins; it also opens L-type calcium channels thereby increasing calcium influx for the augmentation only12. In the rat arterial smooth muscle, on the other hand, opening of T-type calcium channels contributes to calcium influx and hence contraction24; thymoquinone causes augmentation by favoring this mechanism while activation of L-type calcium channels and ROCK do not seem to be involved (Fig. 11)12. The difference in dependency on L-type (porcine coronary arteries) and T-type (rat aortae) calcium channels of the augmentation with thymoquinone confirms the different expression patterns of voltage-dependent calcium channels depending on the species or the vascular bed studied: L-type voltage-dependent calcium channels seem the major contributors to voltage-gated calcium entry in coronary myocytes25, while in the rat aortae, both L-type and T-type voltage-dependent calcium channels are equally expressed26.

Fig. 11
Mechanism underlying the augmentation of contraction caused by thymoquinone: role of calcium homeostasis. Dependency of the contraction in isolated porcine coronary arteries on activation of (a) L-type voltage-dependent calcium channels and of (b) ROCK; ...

4. Parallelism with hypoxic vasoconstriction

In addition to the pharmacological agent thymoquinone, an endothelium-dependent, NO-mediated augmentation of contraction has been demonstrated with acute hypoxia in isolated canine pulmonary, femoral and coronary arteries27, 28, 29, 30, 31 and in isolated porcine coronary arteries32, 33. There are several similarities in the characteristics of the augmentation by thymoquinone and of that in response to acute hypoxia (Table 1): augmentations to both stimuli (1) can be restored by exogenous NO and by stimulators of sGC in the absence of endothelium or eNOS activation12, 30, 31, 32, 33; (2) do not necessitate the presence of the classical product of sGC, cyclic GMP; and (3) are associated with increased production of cyclic IMP12, 32, 33, which is dependent on eNOS- and sGC-activation12, 33. It thus seems reasonable to conclude that cyclic IMP acts as the second messenger mediating the NO-dependent, biased sGC-dependent augmentation of vasoconstriction caused by both thymoquinone and acute hypoxia.

Table 1
Parallelism between thymoquinone-induced augmentation and hypoxic vasoconstriction.

Although endogenous levels of ITP are lower than those of guanosine triphosphate under normal conditions34, acute hypoxia increases intracellular levels of ITP in smooth muscle cells of isolated porcine coronary arteries, as measured by UPLC–MS/MS33. Therefore, as a mechanistic similarity exists between thymoquinone- and hypoxia-induced augmentations of contractions, thymoquinone also may increase the bioavailability of ITP in vascular smooth muscle cells, although actual measurements of the levels of the substrate remain to be performed.

Despite the similarities, there are some differences between the augmentation by hypoxia and that by thymoquinone. While in porcine coronary arteries they both depend on calcium sensitization mediated by ROCK12, 32, 33, L-type calcium channels are involved only in thymoquinone-induced augmentation12. It is unknown whether or not T-type voltage-dependent calcium influx also plays a role in hypoxic vasoconstriction (Table 1).

5. Importance of the quinone moiety

Comparing the responses to thymoquinone with those to compounds with a similar chemical structure, namely 1,4-benzoquinone (Fig. 12) in rat arteries suggests that the quinone moiety is essential for evoking endothelium-dependent contractions that depend on activation of eNOS and sGC12. Quinones are substrates of NADPH:quinone oxidoreductase (NQO-1), an enzyme expressed abundantly in the vascular wall both at the endothelial35 and at the smooth muscle36 levels. The enzyme, by detoxifying endogenous and xenobiotic quinones and their derivatives, prevents the participation of these substances in redox cycling, hence playing an important role in the defense against oxidative stress37, 38, 39

Fig. 12
Responses to increasing concentrations of (A) thymoquinone and (B) 1,4-benzoquinone in isolated rat aortae, precontracted with phenylephrine (10–8–10–6 mol/L), shown as changes in tension as a percentage of the reference contraction ...

NQO-1 metabolizes thymoquinone, likely because of its structural resemblance to ubiquinone, the natural electron carrier in mitochondria40. Indeed, thymoquinone acts as an electron acceptor during the oxidation of nicotinamide adenine dinucleotide (NADH; an essential cofactor for NQO-1) to NAD+ 41. NQO-1 regulates the NAD+/NADH ratio, the increase of which initiates a signalling cascade involving cluster of differentiation38 and cyclic adenosine diphosphate ribose (cADPR), resulting in calcium mobilization that in endothelial cells can activate eNOS by a protein kinase B/adenosine monophosphate-activated protein kinase-dependent mechanism35 or increase contractility of smooth muscle. Therefore, it is possible that the necessary eNOS-activation for the endothelium-dependent augmentation by thymoquinone to occur is caused at least in part by activation of endothelial NQO-1 upon binding with its substrate (Fig. 13). Whether or not, and how, activated NQO-1 in the vascular smooth muscle cells is involved in the biased activation of sGC remains to be resolved.

Fig. 13
Possible involvement of NQO-1 in biasing sGC activity with quinones. cADPR, cyclic adenosine diphosphate ribose; NADH, nicotinamide adenine dinucleotide, reduced; NAD+, nicotinamide adenine dinucleotide, oxidized; NQO-1, NAD(P)H:quinone oxidoreductase. ...

6. Conclusions

Ex vivo studies in rat and porcine arteries12 reveal for quinones a novel and unique mechanism of action, favouring the occurrence of endothelium-dependent, NO- and sGC-mediated contractions, that depend on interference with calcium homeostasis, similar to that observed during hypoxic vasoconstriction32, 33. These contractions require a biased activation (by endogenous NO or synthetic activators) of sGC with subsequent production of cyclic IMP12, as also demonstrated with acute hypoxia33, 42, 43

Quinone-induced augmentations likely involve activation of NQO-1, their metabolizing enzyme. The increase in NAD+/NADH increases calcium mobility35, favouring production of NO by eNOS which then diffuses to the underlying vascular smooth muscle cells to activate the biased sGC producing cyclic IMP, in turn facilitating contraction. In the absence of experiments performed with purified sGC, it is still uncertain whether or not the biased activity of the enzyme is due to a direct target effect of thymoquinone. Likewise, although the quinone moiety seems essential for thymoquinone-induced augmentations to occur12, the link between NQO-1 activation by quinones and the alteration in sGC-activity resulting in contraction remains to be identified. Moreover, the importance (or not) of the augmenting effect of thymoquinone in vivo remains to be determined.

Hypoxic contractions may contribute to the increased prevalence of cardiovascular complications in cardiac patients with sleep apnea44, 45. By identifying the mechanisms underlying the endothelium-dependent augmentation caused by quinones12 and possibly other agents causing biased activity of sGC, the cellular targets involved in cardiovascular complications due to hypoxia can be studied, facilitating the development of novel strategies to prevent coronary hypoxic vasospasm.


This review is based in part on research conducted with financial support from the General Research Fund (17112914) of the Hong Kong Research Grant Council and from the Seed Funding Programme for Basic Research by University Research Committee of the University of Hong Kong (201511159163). The authors would like to thank Ms. Yee Har Chung and Mr. Godfrey Man for technical assistance and Ms. Ivy Wong for editorial assistance.


Peer review under responsibility of Institute of Materia Medica, Chinese Academy of Medical Sciences and Chinese Pharmaceutical Association.


1. Ernster L., Dallner G. Biochemical, physiological and medical aspects of ubiquinone function. Biochim Biophys Acta. 1995;1271:195–204. [PubMed]
2. Singh U.P., Singh D.P., Maurya S., Maheshwari R., Singh M., Dubey R.S. Investigation on the phenolics of some spices having pharmacotherapeutic properties. J Herb Pharmacother. 2004;4:27–42. [PubMed]
3. Salem M.L. Immunomodulatory and therapeutic properties of the Nigella sativa L. seed. Int Immunopharmacol. 2005;5:1749–1770. [PubMed]
4. Ali B.H., Blunden G. Pharmacological and toxicological properties of Nigella sativa. Phytother Res. 2003;17:299–305. [PubMed]
5. Butt M.S., Sultan M.T. Nigella sativa: reduces the risk of various maladies. Crit Rev Food Sci Nutr. 2010;50:654–665. [PubMed]
6. Amin B., Hosseinzadeh H. Black Cumin (Nigella sativa) and its active constituent, thymoquinone: an overview on the analgesic and anti-inflammatory effects. Planta Med. 2016;82:8–16. [PubMed]
7. Khattab M.M., Nagi M.N. Thymoquinone supplementation attenuates hypertension and renal damage in nitric oxide deficient hypertensive rats. Phytother Res. 2007;21:410–414. [PubMed]
8. El-Agamy D.S., Nader M.A. Attenuation of oxidative stress-induced vascular endothelial dysfunction by thymoquinone. Exp Biol Med. 2012;237:1032–1038. [PubMed]
9. Ghayur M.N., Gilani A.H., Janssen L.J. Intestinal, airway, and cardiovascular relaxant activities of thymoquinone. Evid Based Complement Altern Med. 2012;2012:305319. [PMC free article] [PubMed]
10. Darakhshan S., Pour A.B., Colagar A.H., Sisakhtnezhad S. Thymoquinone and its therapeutic potentials. Pharmacol Res. 2015;95–96:138–158. [PubMed]
11. Suddek G.M. Thymoquinone-induced relaxation of isolated rat pulmonary artery. J Ethnopharmacol. 2010;127:210–214. [PubMed]
12. Detremmerie C.M., Chen Z., Li Z., Alkharfy K.M., Leung S.W., Xu A. Endothelium-dependent contractions of isolated arteries to thymoquinone require biased activity of soluble guanylyl cyclase with subsequent cyclic IMP production. J Pharmacol Exp Ther. 2016;358:558–568. [PubMed]
13. Idris-Khodja N., Schini-Kerth V. Thymoquinone improves aging-related endothelial dysfunction in the rat mesenteric artery. Naunyn-Schmiedeberg׳s Arch Pharmacol. 2012;385:749–758. [PubMed]
14. Detremmerie C.M., Leung S.W., Xu A., Gao Y., Vanhoutte P.M. Biased activation of soluble guanylyl cyclase can cause contraction of isolated arteries. FASEB J. 2016;30:11.
15. Vanhoutte P.M., Zhao Y., Xu A., Leung S.W. Thirty years of saying NO: sources, fate, actions, and misfortunes of the endothelium-derived vasodilator mediator. Circ Res. 2016;119:375–396. [PubMed]
16. Nader M.A., El-Agamy D.S., Suddek G.M. Protective effects of propolis and thymoquinone on development of atherosclerosis in cholesterol-fed rabbits. Arch Pharm Res. 2010;33:637–643. [PubMed]
17. Tang E.H., Leung F.P., Huang Y., Félétou M., So K.F., Man R.Y. Calcium and reactive oxygen species increase in endothelial cells in response to releasers of endothelium-derived contracting factor. Br J Pharmacol. 2007;151:15–23. [PubMed]
18. Vanhoutte P.M., Tang E.H. Endothelium-dependent contractions: when a good guy turns bad! J Physiol. 2008;586:5295–5304. [PubMed]
19. Vanhoutte P.M. Endothelium-dependent contractions in hypertension: when prostacyclin becomes ugly. Hypertension. 2011;57:526–531. [PubMed]
20. Dimmeler S., Fleming I., Fisslthaler B., Hermann C., Busse R., Zeiher A.M. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature. 1999;399:601–605. [PubMed]
21. Beste K.Y., Burhenne H., Kaever V., Stasch J.P., Seifert R. Nucleotidyl cyclase activity of soluble guanylyl cyclase α1β1. Biochemistry. 2012;51:194–204. [PubMed]
22. Beste K.Y., Seifert R. cCMP, cUMP, cTMP, cIMP and cXMP as possible second messengers: development of a hypothesis based on studies with soluble guanylyl cyclase α1β1. Biol Chem. 2013;394:261–270. [PubMed]
23. Somlyo A.P., Somlyo A.V. Ca2+ sensitivity of smooth muscle and nonmuscle myosin II: modulated by G proteins, kinases, and myosin phosphatase. Physiol Rev. 2003;83:1325–1358. [PubMed]
24. Duggan J.A., Tabrizchi R. Influence of T-type Ca2+ (mibefradil) and Cl (indanyloxyacetic acid 94) channel antagonists on α1-adrenoceptor mediated contractions in rat aorta. Can J Physiol Pharmacol. 2000;78:714–720. [PubMed]
25. Quignard J.F., Frapier J.M., Harricane M.C., Albat B., Nargeot J., Richard S. Voltage-gated calcium channel currents in human coronary myocytes. Regulation by cyclic GMP and nitric oxide. J Clin Investig. 1997;99:185–193. [PubMed]
26. Ball C.J., Wilson D.P., Turner S.P., Saint D.A., Beltrame J.F. Heterogeneity of L- and T-channels in the vasculature: rationale for the efficacy of combined L- and T-blockade. Hypertension. 2009;53:654–660. [PubMed]
27. De Mey J.G., Vanhoutte P.M. Heterogeneous behavior of the canine arterial and venous wall. Importance of the endothelium. Circ Res. 1982;51:439–447. [PubMed]
28. De Mey J.G., Vanhoutte P.M. Anoxia and endothelium-dependent reactivity of the canine femoral artery. J Physiol. 1983;335:65–74. [PubMed]
29. Rubanyi G.M., Vanhoutte P.M. Hypoxia releases a vasoconstrictor substance from the canine vascular endothelium. J Physiol. 1985;364:45–56. [PubMed]
30. Gräser T., Vanhoutte P.M. Hypoxic contraction of canine coronary arteries: role of endothelium and cGMP. Am J Physiol Heart Circ Physiol. 1991;261:H1769–H1777. [PubMed]
31. Pearson P.J., Lin P.J., Schaff H.V., Vanhoutte P.M. Augmented endothelium-dependent constriction to hypoxia early and late following reperfusion of the canine coronary artery. Clin Exp Pharmacol Physiol. 1996;23:634–641. [PubMed]
32. Chan C.K., Mak J., Gao Y., Man R.Y., Vanhoutte P.M. Endothelium-derived NO, but not cyclic GMP, is required for hypoxic augmentation in isolated porcine coronary arteries. Am J Physiol Heart Circ Physiol. 2011;301:H2313–H2321. [PubMed]
33. Chen Z., Zhang X., Ying L., Dou D., Li Y., Bai Y. cIMP synthesized by sGC as a mediator of hypoxic contraction of coronary arteries. Am J Physiol Heart Circ Physiol. 2014;307:H328–H336. [PubMed]
34. Göttle M., Burhenne H., Sutcliffe D., Jinnah H.A. Purine metabolism during neuronal differentiation: the relevance of purine synthesis and recycling. J Neurochem. 2013;127:805–818. [PubMed]
35. Kim Y.H., Hwang J.H., Noh J.R., Gang G.T., Kim D.H., Son H.Y. Activation of NAD(P)H:quinone oxidoreductase ameliorates spontaneous hypertension in an animal model via modulation of eNOS activity. Cardiovasc Res. 2011;91:519–527. [PubMed]
36. Zhu H., Jia Z., Mahaney J.E., Ross D., Misra H.P., Trush M.A. The highly expressed and inducible endogenous NAD(P)H:quinone oxidoreductase 1 in cardiovascular cells acts as a potential superoxide scavenger. Cardiovasc Toxicol. 2007;7:202–211. [PubMed]
37. Riley R.J., Workman P. DT-diaphorase and cancer chemotherapy. Biochem Pharmacol. 1992;43:1657–1669. [PubMed]
38. Ross D., Kepa J.K., Winski S.L., Beall H.D., Anwar A., Siegel D. NAD(P)H:quinone oxidoreductase 1 (NQO1): chemoprotection, bioactivation, gene regulation and genetic polymorphisms. Chem Biol Interact. 2000;129:77–97. [PubMed]
39. Han S.J., Kang E.S., Kim H.J., Kim S.H., Chun S.W., Ahn C.W. The C609T variant of NQO1 is associated with carotid artery plaques in patients with type 2 diabetes. Mol Genet Metab. 2009;97:85–90. [PubMed]
40. Sutton K.M., Doucette C.D., Hoskin D.W. NADPH quinone oxidoreductase 1 mediates breast cancer cell resistance to thymoquinone-induced apoptosis. Biochem Biophys Res Commun. 2012;426:421–426. [PubMed]
41. Staniek K., Gille L. Is thymoquinone an antioxidant? BMC Pharmacol. 2010;10:A9.
42. Gao Y., Vanhoutte P.M. Tissues cIMPly do not lie. Naunyn-Schmiedeberg׳S Arch Pharmacol. 2014;387:901–903. [PubMed]
43. Gao Y., Chen Z., Leung S.W., Vanhoutte P.M. Hypoxic vasospasm mediated by cIMP: when soluble guanylyl cyclase turns bad. J Cardiovasc Pharmacol. 2015;65:545–548. [PubMed]
44. Butt M., Khair O.A., Dwivedi G., Shantsila A., Shantsila E., Lip G.Y. Myocardial perfusion by myocardial contrast echocardiography and endothelial dysfunction in obstructive sleep apnea. Hypertension. 2011;58:417–424. [PubMed]
45. Lee C.H., Khoo S.M., Chan M.Y., Wong H.B., Low A.F., Phua Q.H. Severe obstructive sleep apnea and outcomes following myocardial infarction. J Clin Sleep Med. 2011;7:616–621. [PubMed]

Articles from Acta Pharmaceutica Sinica. B are provided here courtesy of Elsevier